TD Cowen Reiterates a Buy Rating on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the best strong buy healthcare stocks to buy now. On July 23, TD Cowen analyst Josh Jennings maintained a Buy rating on Boston Scientific Corporation (NYSE:BSX) and set a price target of $115.00, supporting the rating with the company’s positive outlook and solid financial performance.

Was Jim Cramer Right About Boston Scientific Corporation (BSX)?

A surgeon examining a patient’s brain in an operating room, paramedics nearby.

The analyst told investors that Boston Scientific Corporation’s (NYSE:BSX) Q2 2025 sales and EPS exceeded market expectations. EPS for the quarter was $0.75 and sales reached $5.06 billion, surpassing estimates of $0.73 and $4.89 billion, respectively. Jennings attributed this notable performance to a solid organic sales growth of 17.4%, considerably higher than the company’s guidance of 13-15%.

The firm further reasoned that Boston Scientific Corporation (NYSE:BSX) raised its guidance for 2025, and now expects EPS in the range of $2.95-$2.99 and organic sales growth of 14-15%.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments.

The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.